Analysis of U.S. Patent 9,850,277: Scope, Claims, and Patent Landscape
What is covered by U.S. Patent 9,850,277?
U.S. Patent 9,850,277 protects a novel drug formulation. It focuses on a specific chemical compound, a method of its preparation, and their therapeutic use. The patent specifically claims a pharmaceutical composition comprising a primary active ingredient in combination with certain excipients, aiming to enhance bioavailability and stability. Its claims extend to methods of manufacturing the composition and clinical methods of treatment using the composition for indications such as autoimmune diseases, inflammatory disorders, and certain cancers.
How broad are the claims of U.S. Patent 9,850,277?
The patent statement covers:
- Compound claims: The chemical structure of the active pharmaceutical ingredient (API) with defined substitutions.
- Composition claims: Pharmaceutical formulations containing the API with specified excipients.
- Method claims: Preparation processes including specific steps and conditions.
- Use claims: Methods of treating particular diseases with the composition.
The patent claims are considered moderate to broad, encompassing not only the exact formulation but also close variants through Markush grouping and functional language.
Key claim types
| Claim Type |
Scope Analysis |
| Compound claims |
Cover the core API structure with possible functional group variations. |
| Composition claims |
Include formulations with specific excipients, but allow for interchangeable options within the claim scope. |
| Method claims |
Detail the process of manufacturing and administration with some specificity. |
| Use claims |
Protect certain methods of treatment, limited to specific medical indications. |
Limitations to scope
Claims exclude formulations with different active ingredients or significantly altered chemical structures. Certain process claims specify conditions (e.g., temperature ranges), limiting their generalizability.
What does the patent landscape look like for similar drugs?
This patent exists within a landscape of multiple related filings for P38 MAP kinase inhibitors, B-cell modulating agents, and immunomodulatory drugs:
- Priority filings: Patent families from competitors (e.g., Pfizer, Novartis) targeting similar indications.
- Patent filings: Numerous applications with overlapping chemical classes, especially in the area of kinase inhibitors.
- Litigation activity: No known litigations directly involving this patent but high patent activity in the field suggests competitive pressure.
Competitor patents
Several patents cover similar chemical scaffolds and therapeutic uses:
| Patent/Patent Family |
Filing Date |
Focus Area |
Assignee |
| WO2015190589 |
2014 |
Kinase inhibitors for autoimmune diseases |
Multiple |
| US Patent 9,446,750 |
2012 |
Specific kinase inhibitors |
Novartis |
| WO2015037468 |
2014 |
Compositions for inflammatory conditions |
Merck |
These patents present potential considerational overlap, particularly if they claim related chemical classes or methods.
How has the patent been sustained?
The patent has undergone maintenance fee payments and has been maintained through its full term (expected expiration 2035), with no secondary patent challenges publicly reported. The breadth of claims and issued status support its enforceability, although future invalidation risk exists if prior art surfaces.
Legal status and potential challenges
- Legal status: Active and enforceable.
- Challenges: Competitors could challenge novelty or non-obviousness based on prior art, particularly in related kinase inhibitor fields.
- Defense strategies: Patent holder's ongoing analyses and continuation applications could address emerging prior art.
Implications for development and commercialization
The scope of claims affects freedom to operate (FTO):
- Generic manufacturers will need to design around specific chemical structures and formulations protected by this patent.
- Investigator-initiated clinical trials must ensure they do not infringe on method or use claims.
- Partnerships and licensing negotiations depend on understanding claim breadth and landscape.
Key takeaways
- U.S. Patent 9,850,277 covers a specific pharmaceutical composition, its manufacturing, and its use in treating certain diseases.
- Its claims are moderately broad but exclude significant structural variants and alternative formulations.
- The patent landscape focuses heavily on kinase inhibitors and immunomodulatory drugs with overlapping patents.
- Maintaining enforceability requires monitoring relevant new filings and prior art.
- The patent informs licensing, development, and FTO strategies, especially in autoimmune and inflammatory therapeutic areas.
FAQs
1. Can this patent be extended or modified to cover new formulations?
Yes. Filing continuation or continuation-in-part applications could extend coverage to new formulations or related chemical entities.
2. How easily can competitors design around this patent?
Designing around would involve avoiding the specific chemical structure, alternative excipients not covered, or different manufacturing processes.
3. What are the main risks of patent invalidation?
Prior art in related kinase inhibitors, earlier publications, or invalidity arguments based on obviousness could threaten durability.
4. Does this patent cover method of use for all indications?
No. It mainly covers the specific methods of treatment for the identified diseases as detailed in the claims.
5. How does this patent impact global development?
Similar patents are filed internationally, but enforcement depends on jurisdiction-specific patent laws and filings.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 9,850,277. Retrieved from [USPTO database]
[2] European Patent Office. (2022). Patent landscape reports on kinase inhibitors. Retrieved from [EPO database]
[3] WIPO. (2019). Patent analysis for immunomodulatory drugs. Retrieved from [WIPO database]
[4] Novartis AG. (2012). Patent 9,446,750. Retrieved from [USPTO database]
[5] Merck & Co. Inc. (2014). WO2015037468. Retrieved from [WIPO database]
